KRRO Korro Bio, Inc.

NASDAQ
$13.28

Korro Bio, Inc. (KRRO) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $1.25 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +15.5% since its last earnings release on August 6, 2026.

Korro Bio Beat Consensus Estimates
Thursday, August 6, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 7:00 AM ET
Earnings Whisper
-
vs ($1.25)
Rev est $1.5M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $13.04

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Korro Bio, Inc.

Korro Bio Inc. is an RNA editing company focused on the discovery and development of a new class of precision genetic medicines for both rare and highly prevalent diseases. Korro Bio Inc., formerly known as Frequency Therapeutics Inc., is based in LEXINGTON, Mass.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow